Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 214

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial

Kim, Chan Joon, Park, Mahn-Won, Kim, Min Chul, Choo, Eun-Ho, Hwang, Byung-Hee, Lee, Kwan Yong, Choi, Yun Seok, Kim, Hee-Yeol, Yoo, Ki-Dong, Jeon, Doo-Soo, Shin, Eun-Seok, Jeong, Young-Hoon, Seung, Ki-Bae, Jeong, Myung Ho, Yim, Hyeon Woo, Ahn, Youngkeun, Chang, Kiyuk, Kim, Chan Joon, Park, Mahn-Won, Kim, Min Chul, Choo, Eun-Ho, Hwang, Byung-Hee, Lee, Kwan Yong, Choi, Yun Seok, Kim, Hee-Yeol, Yoo, Ki-Dong, Jeon, Doo-Soo, Shin, Eun-Seok, Jeong, Yong-Hoon, Seung, Ki-Bae, Jeon, Myung Ho, Ahn, Youngkeun, Chang, Kiyuk, Oh, Ju-Hyeon, Ha, Sang Jin, Baek, Ju Yeol, Jung, Kyung Tae, Doh, Joon-Hyung, Kim, Won, Kim, Dong-Bin, Cha, Kwang Soo, Yoon, Myeong-Ho, Hur, Seung-Ho, Lee, Seung-Hwan, Cho, Byung-Ryul, Park, Jong-Seon, Koh, Jin Shin, Kim, Sang-Hyun, Cho, Jang Hyun, Shim, Byung Joo, Kim, Sang Wook, Jang, Jae-Sik, Kim, Kee-Sik, Shin, Won-Yong, Sung, Ki-Chul · 2021 · The Lancet

Abstract

BACKGROUND In patients with acute myocardial infarction receiving potent antiplatelet therapy, the bleeding risk remains high during the maintenance phase. We sought data on a uniform unguided de-escalation strategy of dual antiplatelet therapy (DAPT) from ticagrelor to clopidogrel after acute myocardial infarction. METHODS In this open-label, assessor-masked, multicentre, non-inferiority, randomised trial (TALOS-AMI), patients at 32 institutes in South Korea with acute myocardial infarction receiving aspirin and ticagrelor without major ischaemic or bleeding events during the first month after index percutaneous coronary intervention (PCI) were randomly assigned in a 1:1 ratio to a de-escalation (clopidogrel plus aspirin) or active control (ticagrelor plus aspirin) group. Unguided de-escalation without a loading dose of clopidogrel was adopted when switching from ticagrelor to clopidogrel. The primary endpoint was a composite of cardiovascular death, myocardial infarction, stroke, or bleeding type 2, 3, or 5 according to Bleeding Academic Research Consortium (BARC) criteria from 1 to 12 months. A non-inferiority test was done to assess the safety and efficacy of de-escalation DAPT compared with standard treatment. The hazard ratio (HR) for de-escalation versus active control group in a stratified Cox proportional hazards model was assessed for non-inferiority by means of an HR margin of 1·34, which equates to an absolute difference of 3·0% in the intention-to-treat population and, if significant, a superiority test was done subsequently. To ensure statistical robustness, additional analyses were also done in the per-protocol population. This trial is registered at ClinicalTrials.gov, NCT02018055. FINDINGS From Feb 26, 2014, to Dec 31, 2018, from 2901 patients screened, 2697 patients were randomly assigned: 1349 patients to de-escalation and 1348 to active control groups. At 12 months, the primary endpoints occurred in 59 (4·6%) in the de-escalation group and 104 (8·2%) patients in the active control group (pnon-inferiority<0·001; HR 0·55 [95% CI 0·40-0·76], psuperiority=0·0001). There was no significant difference in composite of cardiovascular death, myocardial infarction, or stroke between de-escalation (2·1%) and the active control group (3·1%; HR 0·69; 95% CI 0·42-1·14, p=0·15). Composite of BARC 2, 3, or 5 bleeding occurred less frequently in the de-escalation group (3·0% vs 5·6%, HR 0·52; 95% CI 0·35-0·77, p=0·0012). INTERPRETATION In stabilised patients with acute myocardial infarction after index PCI, a uniform unguided de-escalation strategy significantly reduced the risk of net clinical events up to 12 months, mainly by reducing the bleeding events. FUNDING ChongKunDang Pharm, Medtronic, Abbott, and Boston Scientific.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)01445-8

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 214

Metadata

Authors
Kim, C. J., Park, M.-W., Kim, M. C., Choo, E.-H., Hwang, B.-H., Lee, K. Y., Choi, Y. S., Kim, H.-Y., Yoo, K.-D., Jeon, D.-S., Shin, E.-S., Jeong, Y.-H., Seung, K.-B., Jeong, M. H., Yim, H. W., Ahn, Y., Chang, K., Kim, C. J., Park, M.-W., Kim, M. C., Choo, E.-H., Hwang, B.-H., Lee, K. Y., Choi, Y. S., Kim, H.-Y., Yoo, K.-D., Jeon, D.-S., Shin, E.-S., Jeong, Y.-H., Seung, K.-B., Jeon, M. H., Ahn, Y., Chang, K., Oh, J.-H., Ha, S. J., Baek, J. Y., Jung, K. T., Doh, J.-H., Kim, W., Kim, D.-B., Cha, K. S., Yoon, M.-H., Hur, S.-H., Lee, S.-H., Cho, B.-R., Park, J.-S., Koh, J. S., Kim, S.-H., Cho, J. H., Shim, B. J., Kim, S. W., Jang, J.-S., Kim, K.-S., Shin, W.-Y., & Sung, K.-C.
Venue
The Lancet
Publisher
Elsevier BV
Published
2021-10
Volume
398
Issue
10308
Pages
1305-1316
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3201989641
Cited by
214
References
6
FWCI
18.94
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. https://app.cochat.ai/papers/10.1016/s0140-6736(21)01445-8
The paper
Kim, C. J., Park, M.-W., Kim, M. C., Choo, E.-H., Hwang, B.-H., Lee, K. Y., Choi, Y. S., Kim, H.-Y., Yoo, K.-D., Jeon, D.-S., Shin, E.-S., Jeong, Y.-H., Seung, K.-B., Jeong, M. H., Yim, H. W., Ahn, Y., Chang, K., Kim, C. J., Park, M.-W., . . . Sung, K.-C. (2021). Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. The Lancet. https://doi.org/10.1016/s0140-6736(21)01445-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.